Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.80 - $235.96
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$6.28M
Enterprise Value$634.47K
Total Cash (Recent Filing)$14.53M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 06, 2026EPS Estimate
-6.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.47
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of Lead CandidateConsistently high clinical benefit and remission rates with favorable safety for mipletamig support a durable competitive edge in frontline AML. These data increase the likelihood of advancing to pivotal studies, enhance regulatory and partner interest, and materially de-risk the program versus early-stage peers.
Strategic Radiopharmaceutical CollaborationThe Niowave partnership diversifies Aptevo's pipeline into targeted alpha therapies and secures isotope access and shared development resources. Equity alignment and reciprocal IP reduce execution risk and capital needs while positioning Aptevo in a growing radiopharma segment with structural supply constraints.
Strengthened Scientific LeadershipHiring an experienced CSO with deep oncology R&D experience improves long-term drug development execution, translational strategy, and trial design. Strong scientific leadership raises the odds of efficient dose selection, robust translational biomarker programs, and credible partner engagements.
Bears Say
No Meaningful Revenue And Persistent LossesSustained operating losses and effectively zero product revenue mean the company must rely on external financing or partnerships to fund development. This structural cash burn elevates dilution risk and constrains strategic flexibility, affecting ability to execute multi-program development over the medium term.
Limited Balance Sheet And Dilution RiskWhile leverage has improved, modest equity and historical volatility imply limited financial cushion. With ongoing negative cash flow, Aptevo may need near-term capital raises, which can dilute shareholders and delay programs; this is a persistent structural constraint on growth execution.
Clinical-stage Business Model Dependent On PartnershipsReliance on collaboration and milestone-based revenue creates lumpy, uncertain cash inflows and ties program advancement to partner actions. Without marketed products, durable cash generation is weak, making long-term planning and sustained independent development more challenging.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.80 and its highest was $235.96 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $6.28M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$6.41 earnings per share for the quarter, missing the consensus estimate of -$5.6 by -$0.81.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -6.2.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,246,105 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$6.41 in its last earnings report, missing expectations of -$5.6. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.09% Insiders
1.79% Mutual Funds
<0.01% Other Institutional Investors
96.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---